ESMO 2016

07–11 October 2016 | Copenhagen, Denmark

ESMO 2016

07–11 October 2016 | Copenhagen, Denmark
ESMO 2016: Q&A on Friday’s press briefs 15:11
ESMO 2016: Q&A on Friday’s press briefs
Andrés Cervantes et al. • 7 Oct 2016
Results of KEYNOTE-024 trial of pembrolizumab in NSCLC 1:48
Results of KEYNOTE-024 trial of pembrolizumab in NSCLC
Martin Reck • 7 Oct 2016
Biomarkers of response and resistance in kidney cancer 2:37
Biomarkers of response and resistance in kidney cancer
Toni Choueiri • 7 Oct 2016
Next steps for niraparib for ovarian cancer following on from the ENGOT-OV16/NOVA trial 1:14
Next steps for niraparib for ovarian cancer following on from the ENGOT-OV16/NOVA trial
Sven Mahner • 7 Oct 2016
Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprising 3:10
Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprising
Ursula Matulonis • 7 Oct 2016
The promising potential of PARP inhibitors in ovarian cancer 3:09
The promising potential of PARP inhibitors in ovarian cancer
Jonathan Ledermann • 7 Oct 2016
Trial design of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer 2:26
Trial design of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer
Mansoor Mirza • 7 Oct 2016
CABOSUN trial of cabozantinib – could it change how we treat frontline RCC? 4:12
CABOSUN trial of cabozantinib – could it change how we treat frontline RCC?
Toni Choueiri
Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancer 9:25
Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancer
Mansoor Mirza
Panitumumab data presented at ESMO 2016: depth of response and selecting the right patients 1:37
Panitumumab data presented at ESMO 2016: depth of response and selecting the right patients
Marc Peeters • 7 Oct 2016
ESMO 2016: Press brief on the key messages of ESMO and its vision for the future 5:22
ESMO 2016: Press brief on the key messages of ESMO and its vision for the future
Fortunato Ciardiello • 7 Oct 2016
ESMO 2016: Press brief on the affordability and access to cancer medicines in Europe 5:51
ESMO 2016: Press brief on the affordability and access to cancer medicines in Europe
Josep Tabernero • 7 Oct 2016
ESMO 2016: From disease treatment to patient care 2:22
ESMO 2016: From disease treatment to patient care
Solange Peters • 7 Oct 2016
ESMO 2016: Press brief on the inquality of access to innovative medicine in Europe for melanoma 5:06
ESMO 2016: Press brief on the inquality of access to innovative medicine in Europe for melanoma
Lidija Kandolf-Sekulovic • 7 Oct 2016

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals